Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23311686 | 0.93 | GPR119 (0.67) | GPR119 | |
| SCHEMBL24111531 | 0.91 | GPR119 (0.53) | GPR119USP30 | |
| SCHEMBL31398187 | 0.91 | GPR119 (0.53) | GPR119USP30 | |
| SCHEMBL22031763 | 0.90 | GPR119 (0.51) | GPR119PIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL28415375 | 0.90 | GPR119 (0.51) | GPR119PIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL28423794 | 0.90 | GPR119 (0.51) | GPR119PIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL31044625 | 0.88 | GPR119 (0.48) | GPR119PIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL28419935 | 0.88 | GPR119 (0.48) | GPR119PIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL31044622 | 0.88 | GPR119 (0.48) | GPR119PIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL28412010 | 0.88 | GPR119 (0.48) | GPR119PIK3CDUSP30PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210392895-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LIMITED (IN) | 2021-12-23 | — | — | US | disclosed |
| WO-2020070610-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LTD. (IN) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210392895-A1 | NOVEL OXADIAZOLES | OXA1L, CYP1B1, CYP1A1 | GPR119 741/4885PIK3CD 2634/4885USP30 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.